Data as of Q4 2025 (Dec 31, 2025)
โณ
Showing Q3 2024 data
Ghost Tree Capital, LLC's Q4 2025 filing not yet available. Expected by Feb 14, 2026.

Ghost Tree Capital, LLC

โ€ขCIK: 1595851โ€ขFiling: Q3 2024

**Ghost Tree Capital, LLC** manages $321M across a portfolio of 52 distinct positions. The fund exhibits a concentrated, sector-specific approach, with top holdings including XBI at $29.6M and BHVN at $17.4M. Significant allocations are also maintained in SRPT ($15.0M), NVO ($13.1M), and 2L9 ($12.9M). This structure suggests a tactical focus on specific market segments within the current investment cycle.

Total AUM
$287.7M
+ $33.3M in options
QoQ Performance
+2.6%
Positions
50
+ 2 options
Top 10 Concentration
43.7%
Latest Filing
Q3 2024

Top Holdings Allocation

XBI
BIOH
XBI9.2%
BIOHAVEN5.4%
SRPT4.7%
NVO4.1%
2L94.0%
AXSM3.8%
TARS3.6%
CATX3.1%

๐Ÿ“ˆ Biggest Buys

XBIPUT
SPDR SER TR
NEW
9.2% of portfolio
โ€”
BIOHAVEN LTD
NEW
5.4% of portfolio
NVO
NOVO-NORDISK A S
NEW
4.1% of portfolio
2L9
BLUEPRINT MEDICINES CORP
+250.0%
4.0% of portfolio
SRPT
SAREPTA THERAPEUTICS INC
+118.2%
4.7% of portfolio

๐Ÿ“‰ Biggest Sells

VRDN
VIRIDIAN THERAPEUTICS INC
-87.2%
0.5% of portfolio
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
-57.2%
2.0% of portfolio
PCVX
VAXCYTE INC
-46.7%
2.8% of portfolio
SLNO
SOLENO THERAPEUTICS INC
-50.0%
2.4% of portfolio
SYRE
SPYRE THERAPEUTICS INC
-76.0%
0.5% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q2 2024

BHVN
BIOHAVEN LTD
SOLD
$17.0M
ALNY
ALNYLAM PHARMACEUTICALS INC
SOLD
$16.6M
ACAD
ACADIA PHARMACEUTICALS INC
SOLD
$3.7M
CABA
CABALETTA BIO INC
SOLD
$2.8M
CYTK
CYTOKINETICS INC
SOLD
$1.8M
+14 more exited positions

Changes from Q2 2024

NEW11 new positions
โ†‘15 increased
โ†“23 decreased

Historical Filings

Q3 2024Q2 2024Q1 2024Q4 2023